Mesoblast (NASDAQ:MESO) Shares Gap Down – Time to Sell?

Mesoblast Limited (NASDAQ:MESO)’s stock price gapped down prior to trading on Wednesday . The stock had previously closed at $20.40, but opened at $19.08. Mesoblast shares last traded at $18.84, with a volume of 62,399 shares changing hands.

Wall Street Analysts Forecast Growth

MESO has been the subject of several recent research reports. Piper Sandler upped their price objective on Mesoblast from $11.00 to $15.00 and gave the stock an “overweight” rating in a research report on Thursday, December 19th. Cantor Fitzgerald raised Mesoblast to a “strong-buy” rating in a research report on Thursday, January 30th. Finally, Jefferies Financial Group cut Mesoblast from a “buy” rating to a “hold” rating in a research report on Monday, December 23rd. One research analyst has rated the stock with a sell rating, one has given a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, Mesoblast has a consensus rating of “Moderate Buy” and a consensus price target of $13.50.

Mesoblast Stock Performance

The company has a current ratio of 1.18, a quick ratio of 1.18 and a debt-to-equity ratio of 0.21. The firm has a fifty day moving average of $16.04 and a 200-day moving average of $10.81.

Institutional Trading of Mesoblast

Institutional investors and hedge funds have recently bought and sold shares of the business. Jane Street Group LLC raised its stake in Mesoblast by 46.4% in the third quarter. Jane Street Group LLC now owns 85,102 shares of the company’s stock valued at $695,000 after buying an additional 26,959 shares during the period. Marshall Wace LLP bought a new position in shares of Mesoblast during the second quarter worth approximately $562,000. Ballentine Partners LLC bought a new position in shares of Mesoblast during the fourth quarter worth approximately $222,000. Signaturefd LLC increased its stake in shares of Mesoblast by 128.7% during the third quarter. Signaturefd LLC now owns 5,506 shares of the company’s stock worth $45,000 after purchasing an additional 3,099 shares during the period. Finally, Creative Planning bought a new position in shares of Mesoblast during the third quarter worth approximately $147,000. Institutional investors own 1.43% of the company’s stock.

Mesoblast Company Profile

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.